Earnings Updates, In Brief: Momenta, Acorda, Sangamo, Lundbeck, Actelion, Alnylam, Seattle Genetics
Executive Summary
Year-end earnings reports from the biotech crowd show movement in the biosimilar field, faith in RNAi, high value for rare disease approaches and strategies to defend and grow primary assets.
You may also be interested in...
Next Biosimilars Hurdle: Winning Over Physicians
Data necessary for regulatory approval may not be sufficient for prescribers, Pfizer’s Sophie Opdyke tells Pharmaceutical Strategy Conference.
How And Why Genzyme And Alnylam Expanded Their Alliance
Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.
The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan
Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.